NEW YORK, Nov. 13, 2013 /PRNewswire/ -- Pomerantz Grossman Hufford Dahlstrom & Gross LLP is investigating claims on behalf of investors of ViroPharma, Inc. ("ViroPharma" or the "Company") (NASDAQ: VPHM) (ISIN: US9282411084) (CUSIP: 928241108) concerning the proposed acquisition of ViroPharma by Shire Plc. The investigation concerns whether the ViroPharma directors are breaching their fiduciary duties by failing to adequately shop the Company and maximize shareholder value. Under the terms of the agreement, ViroPharma shareholders will receive $50.00 per share in cash for each share of ViroPharma common stock. However, (i) the price to Revenue multiple is below the average of comparable transactions; (ii) synergies may not be fully reflected in offered price; and (iii) the current Management team may stay on after the merger. ViroPharma shareholders seeking more information about this acquisition are advised to contact Robert Willoughby at email@example.com or 212-661-1100 or 888-476-6529, ext. 237. The Pomerantz Firm, with offices in New York, Chicago, Florida, and San Diego, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 75 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of defrauded investors. See www.pomerantzlaw.com. CONTACT:Robert WilloughbyPomerantz Grossman Hufford Dahlstrom & Gross LLP212-661-1100 ext. 237 firstname.lastname@example.org SOURCE Pomerantz Grossman Hufford Dahlstrom & Gross LLP
Irish pharmaceuticals company Shire said on Friday it had arranged to hand its Dermagraft skin substitute to Organogenesis and take a $650 million loss on the disposal, which unwinds a major part of an acquisition it made less than three years ago.